The 6th Conference on Retroviruses and Opportunistic Infections included some significant information on initial HIV therapy. Data from the Dupont 006 efavirenz (EFV)/AZT/3TC trial are provided in a table and demonstrate the excellent potency and durability of efavirenz. The Atlantic Trial compares three 3-drug regimens. Twenty-four week results are presented, including evidence that median increases in CD4 counts are similar between the groups. In addition, researchers from the conference presented 24-week data from two open trials of ABT 378 in combination with Ritonavir. This drug shows great tolerability and potency. Details from each trial are discussed.
|Original language||English (US)|
|Pages (from-to)||1, 10-11|
|Journal||The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service|
|State||Published - Mar 1999|
ASJC Scopus subject areas